Dr. Edwin de Wit

Currently Clinical Program Director and Medical Affairs Director for several clients: • Responsible for the conduct of clinical trials at a small start-up company in oncology. • Driving pre-launch medical activities for a new drug in hematology (rare disease). • Serves as regional medical director for a hematological compound in phase 2.

Building the medical department of Onyx in Europe & MEA in support of the global expansion of the company. Therapeutic area: Oncology/Hematology • Key member of the Regional Leadership Team; • Lead the European medical strategies and represent the company in key discussions with opinion leaders, research networks and authorities

Leader of the Oncology Clinical Department of a global pharmaceutical company’s US headquarters. • Head of Clinical Research group responsible for developing novel anti-cancer agents • People development and management of more than 20 staff • Cross-collaboration Clinical Research, Medical Affairs and Marketing • Medical Affairs activities for the lead oncology program • Stakeholder management: KOLs, academic institutions and major research networks

Clinical leader of a full clinical development program in Oncology in various solid tumor indications. Management responsibility for medical monitors and administrative staff.

Clinical leader of phase 3 clinical development programs; Management responsibility for a team of clinicians, clinical scientists and administrative staff. Therapeutic areas: Oncology and Urology

Medical Director of start-up biopharma company founded to develop compounds in Critical Care. Responsibility for the medical aspects of the company’s development projects. Therapeutic area: Critical care

Global Project Leader / Medical Director for a phase 3 development compound in obstetrics. Successful in obtaining regulatory approval of a new compound in EU and other countries. Clinical Project Leader (interim) of global phase 3 trial in urology

Design and implementation of phase 4 trials in the Netherlands. Management of Dutch centers of pivotal phase 3 registration trials.